Clinical trials
Immunization clinical trials
Below are recruiting immunization clinical trials, each written for real people, not researchers. We’re tracking 973 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06829238RecruitingPhase 4
Metformin to boost immune function in people with a history of drug use
This study tests whether metformin, a common diabetes drug, can help restore immune system balance in people who have used injection drugs in the past. It includes both people living with HIV and those who are HIV-negative.
Birmingham, AlabamaAges 18–64 - NCT06819735RecruitingPhase 1/Phase 2
Testing DT-7012 in Advanced Solid Tumors
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06817395Recruiting
Thinking and memory in chronic ITP
This study looks at whether chronic or persistent immune thrombocytopenia (ITP) affects thinking and memory. If you have had low platelet counts for 3 months or more and have been treated for ITP, you may help researchers understand how the condition can impact the brain.
Boston, MassachusettsAges 18 years+ - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06752356RecruitingPhase 3
A study of a new IVIG treatment for CIDP
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
Stamford, ConnecticutAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06132984Recruiting
Heart MRI monitoring for immunotherapy-related heart issues
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
Chengdu, SichuanAges 18–75 - NCT06723106Enrolling by invitationPhase 1
Long-term safety study of RAY121 for immune conditions
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Camperdown, New South WalesAges 18–85 - NCT06722235RecruitingPhase 3
Mezagitamab for chronic immune thrombocytopenia
This study tests a new medicine called mezagitamab for people with chronic ITP (low platelets for over a year). The medicine may help raise your platelet count and reduce bleeding risk.
Hot Springs, ArkansasAges 18 years+ - NCT06721013RecruitingPhase 1/Phase 2
Study of Pirtobrutinib for immune thrombocytopenia
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06715982RecruitingPhase 2
JAK inhibitor for severe skin rash from immunotherapy
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
Quzhou, ZhejiangAges 18–80 - NCT06706102RecruitingPhase 4
Study of Tiny Blood Particles During CAR-T Therapy
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
Saint-EtienneAges 18 years+ - NCT06708429Recruiting
Lynch syndrome and gut immune system study
This study looks at how the immune system interacts with the gut lining in people with Lynch syndrome and those without. It may help us better understand how Lynch syndrome affects the body.
Monrovia, CaliforniaAges 18 years+ - NCT06680843Recruiting
Immune signatures from animal virus exposure in Cambodia
This study aims to understand how people's immune systems respond to viruses that spread from animals to humans (zoonotic viruses). If you have had recent contact with potentially infected animals in Cambodia, your participation can help researchers find ways to detect and prevent future outbreaks.
BattambangAges 18–65 - NCT06643247Recruiting
Electroacupuncture for shingles pain and immune response
This study tests if electroacupuncture can help calm the immune system and reduce shingles pain. It is for women aged 50–70 who have had a shingles rash for 7 days or less and have not yet taken any medication for their shingles.
Hangzhou, ZhejiangAges 50–70 - NCT06639854Recruiting
CMV immunity test to guide antiviral prevention after transplant
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Houston, TexasAges 18 years+ - NCT06623461RecruitingPhase 2
Fecal transplant with immunotherapy for advanced melanoma
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Abbotsford British Columbia, British ColumbiaAges 18 years+ - NCT06599697RecruitingPhase 2
IVIG for anti-HMGCR muscle disease
This trial tests if IVIG (intravenous immunoglobulin, a donated blood product that helps the immune system) can improve muscle strength and reduce damage in people with anti-HMGCR immune-mediated necrotizing myopathy (a rare muscle disease where the immune system attacks muscle cells). It may help you if your muscle weakness is not too severe and you haven't tried IVIG before.
Birmingham, AlabamaAges 16 years+ - NCT06565078Recruiting
Safety study of immune globulin for primary immunodeficiency
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
Tokyo, TokyoAges Any age - NCT06154915Recruiting
Immune cells in diabetic foot ulcers
This study looks at immune cells in chronic foot ulcers caused by diabetes. It may help researchers understand how these ulcers heal, which could lead to better treatments.
Huddinge, Stockholm CountyAges 18–98 - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06548789RecruitingPhase 2
Diet and immunotherapy before surgery for melanoma
This study tests whether adding a special diet (with prebiotic foods) to standard immunotherapy before surgery helps your body fight melanoma better. It may improve how well the treatment works and reduce side effects.
Houston, TexasAges 18 years+ - NCT06519565RecruitingEarly Phase 1
Testing PRG-1801 for hard-to-treat immune thrombocytopenia
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Wuhan, HubeiAges 18 years+ - NCT06478277Recruiting
Heart disease and inflammatory disease registry study
This registry study tracks people with immune-mediated inflammatory diseases (like rheumatoid arthritis or lupus) to better understand their risk of heart disease. It aims to improve prevention and care by collecting health information over time.
Edinburgh, ScotlandAges 18 years+
Hear when a new Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunization?
- Yes. Clin2 currently lists 973 recruiting immunization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.